< Back to previous page
Researcher
Kevin Punie
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From28 Feb 2017 → Today
Projects
1 - 2 of 2
- Novel biomarkers in the risk stratification, surveillance and treatment of young breast cancer patients and germline carriers of pathogenic variants in TP53.From1 Sep 2020 → 13 Feb 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Relapse in breast and gynaecological cancers.From1 Feb 2019 → 1 Oct 2021Funding: Private funding of national origin - undefined
Publications
1 - 10 of 83
- Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer : A plain language summary(2024)Published in: Future OncologyISSN: 1479-6694
- Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers(2024)Published in: ANNALS OF ONCOLOGYISSN: 0923-7534Issue: 9Volume: 35Pages: 792 - 804
- Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study(2024)Published in: CancerISSN: 0008-543XIssue: 16Volume: 130Pages: 2746 - 2762
- Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression(2024)Published in: JOURNAL OF CLINICAL ONCOLOGYISSN: 0732-183XIssue: 15Volume: 42
- Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer(2024)Published in: npj Breast CancerIssue: 1Volume: 10
- Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial(2023)Published in: Nature CommunicationsISSN: 2041-1723Issue: 1Volume: 14
- Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis(2023)Published in: Journal of Cancer Research and Clinical OncologyISSN: 0171-5216Issue: 7Volume: 149Pages: 3075 - 3080
- COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases(2023)Published in: ESMO OpenISSN: 2059-7029Issue: 3Volume: 8
- Germline TP53 pathogenic variants and breast cancer: A narrative review(2023)Published in: Cancer Treatment ReviewsISSN: 0305-7372Volume: 114
- Career and Professional Development for Young Oncologists(2023)Published in: Oncology Research And TreatmentISSN: 2296-5270Issue: 3Volume: 46Pages: 67 - 70